此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma

2026年9月23日 更新者:Children's Oncology Group

A Phase 1/2 Trial of Chemoradiotherapy With 5-Fluorouracil and Maintenance Chemotherapy for High-Risk Posterior Fossa Ependymoma

This phase I/II trial tests the safety, side effects best dose and how well giving fluorouracil and tretinoin along with standard of care radiation therapy works for the treatment of high risk posterior fossa ependymoma that has not spread to other parts of the body (localized). Fluorouracil is a type medication called an antimetabolite. It works by stopping cells from making DNA and it may kill tumor cells. Tretinoin, also called all-trans retinoic acid (ATRA), retinoic acid, and vitamin A acid is in a class of medications called retinoids. It is made in the body from vitamin A and helps cells to grow and develop, especially in the embryo. Laboratory made form of tretinoin works by slowing or stopping the growth of tumor cells. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Giving fluorouracil and tretinoin along with standard of care radiation therapy may be safe, tolerable and/or effective in treating patients with localized high risk posterior fossa ependymoma.

研究概览

详细说明

PRIMARY OBJECTIVE:

I. To assess the safety of intravenous (IV) bolus fluorouracil (5-FU) in combination with standard-of-care radiation therapy and to determine the recommended phase 2 dose (RP2D) when administered concurrently with radiation therapy (RT) in children with newly-diagnosed localized high-risk posterior fossa type A (PFA) ependymoma. (Phase 1) II. To determine the safety of and RP2D for oral tretinoin (all trans retinoic acid [ATRA]) on an intermittent schedule in combination with bolus IV fluorouracil (5-FU) in children with newly-diagnosed localized high-risk PFA ependymoma as maintenance therapy after fluorouracil-based chemoradiotherapy. (Phase 1) III. To compare event-free survival (EFS) in children with newly-diagnosed high-risk PFA ependymoma treated with resection, radiation therapy (RT), fluorouracil (5-FU), and ATRA at the RP2D with historical controls from ACNS0831. (Phase 2)

SECONDARY OBJECTIVES:

I. To preliminarily define the antitumor activity of IV bolus fluorouracil (5-FU) in combination with standard-of-care radiation therapy and of oral tretinoin (ATRA) on an intermittent schedule in combination with bolus IV fluorouracil (5-FU) maintenance for pediatric patients with newly diagnosed localized high-risk PFA ependymoma within the confines of a Phase 1 study. (Phase 1) II. To estimate overall survival (OS) in children with newly-diagnosed high-risk PFA ependymoma treated with resection, RT, fluorouracil (5-FU), and oral tretinoin (ATRA) at the RP2D. (Phase 2)

EXPLORATORY OBJECTIVES:

I. To correlate presence of tumor cell free deoxyribonucleic acid (DNA) with methylation profiling and clinical outcome. (Phase 1/2) II. To correlate histopathologic grade, gene expression profiles, epigenetic profiles and chromosome copy number status with clinical outcome. (Phase 1/2) III. To bank tumor, blood and cerebrospinal fluid specimens for future studies and assessment of immune and molecular signatures that may predict response or resistance in high-risk PFA ependymoma. (Phase 1/2)

OUTLINE: This is a phase I, dose-escalation study of fluorouracil and tretinoin followed by a dose-expansion and phase II study.

CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy over 6 or 7 weeks. Starting on day 1, 2 or 3 of radiation, patients receive fluorouracil IV over 3-15 minutes on days 1 and 15, days 1, 8 and 15, or days 1, 8, 15 and 22 depending upon assigned dose level. Treatment is given in the absence of disease progression or unacceptable toxicity.

MAINTENANCE CHEMOTHERAPY: Four weeks after completion of chemoradiotherapy, patients receive fluorouracil IV on days 1, 8, 15 and 22 of each cycle and tretinoin orally (PO) three times daily (TID) on days 1-3, 8-10, 15-17 and 22-24 of each cycle. Cycles repeat every 42 days for 6 cycles in the absence of disease progression or unacceptable toxicity.

Patients undergo echocardiography or multigated acquisition (MUGA) scan, magnetic resonance imaging (MRI), lumbar puncture, and optional blood sample collection throughout the study.

After completion of study treatment, patients are followed up at relapse, every 4 months for years 1-3, then every 6 months for years 3-5.

研究类型

介入性

注册 (估计的)

70

阶段

  • 阶段2
  • 阶段1

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1年 至 21年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • PRE-ENROLLMENT: Patients must be > 12 months and < 21 years of age at the time of enrollment

  • PRE-ENROLLMENT: Patient has newly diagnosed posterior fossa ependymoma based on institutional pathologic diagnosis

  • PRE-ENROLLMENT: The patient and/or their parents or legal guardians must have signed informed consent for APEC14B1 Part A - Eligibility Screening

  • PRE-ENROLLMENT: If relying on APEC14B1-MCI for molecular characterization, required specimens for molecular characterization should be submitted as soon as possible, preferably within 5 calendar days of definitive surgery

  • Patients must be > 12 months and < 21 years at the time of study enrollment

  • Patients must be newly diagnosed, localized and have eligibility confirmed by central review of molecular reports

  • Histologically confirmed diagnosis of Posterior fossa ependymoma, group PFA

  • Molecular high risk features including Chromosome 1q gain and/or chromosome 6q loss

  • Patients must be enrolled on study within 56 days of definitive surgical resection. If applicable, the day of subsequent resection to remove residual tumor will be regarded as the day of definitive surgery and must be within a month (31 days) of the initial resection

  • Patients must have negative lumbar CSF cytology.

    • Note: CSF cytology for staging should be performed no sooner than 14 days post operatively to avoid false positive CSF. Ideally, CSF should be obtained between Day 14 and Day 21 to allow for final staging status before enrollment onto the study. Patients with positive lumbar CSF cytology obtained 0 to 14 days after surgery should have lumbar cytology repeated to determine eligibility and final CSF status. Patients with negative CSF lumbar cytology from lumbar puncture obtained 0 to 14 days after surgery do not need cytology repeated. Patients with negative CSF cytology from lumbar puncture obtained prior to surgery do not need cytology repeated post-operatively.
    • CSF cytology does not need to be repeated if within 87 days prior to enrollment regardless of timing
  • Patients must have localized disease. Pre and post-operative whole brain MRI with and without gadolinium and spine MRI with gadolinium must be performed

    • Disease/staging imaging studies, including MRI brain (post operative) and spine (pre or post-operative), must be obtained within 31 days prior to enrollment and start of protocol therapy (repeat if necessary)
  • No prior treatment other than surgical intervention and corticosteroids. Patients are allowed to have had more than one surgical resection prior to enrollment. For patients who have subsequent surgery, the day of the subsequent resection to remove residual tumor will be regarded as the day of definitive surgery and must be within a month (31 days) of initial resection

  • Known HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • Peripheral absolute neutrophil count (ANC) ≥ 1000/ µL (performed within 7 days prior to enrollment)

  • Platelet count ≥ 100,000/µL (transfusion independent) (performed within 7 days prior to enrollment)

  • Hemoglobin ≥ 8 g/dL (may receive red blood cell [RBC] transfusions) (transfusion independent) (performed within 7 days prior to enrollment)

  • Adequate Renal Function Defined As:

    • A serum creatinine based on age/sex as follows (performed within 7 days prior to enrollment) OR

      • 1 to < 2 years: Maximum serum creatinine 0.6 mg/dL (male), 0.6 mg/dL (female)

      • 2 to < 6 years: Maximum serum creatinine 0.8 mg/dL (male), 0.8 mg/dL (female)

      • 6 to < 10 years: Maximum serum creatinine 1 mg/dL (male), 1 mg/dL (female)

      • 10 to < 13 years: Maximum serum creatinine 1.2 mg/dL (male), 1.2 mg/dL (female)

      • 13 to < 16 years: Maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female)

      • >= 16 years: Maximum serum creatinine 1.7 mg/dL (male),1.4 mg/dL (female)

        • The threshold creatinine values in this Table were derived from the Schwartz formula for estimating glomerular filtration rate (GFR) utilizing child length and stature data published by the Center for Disease Control (CDC)
    • a 24-hour urine Creatinine clearance ≥ 50 mL/min/1.73 m^2 (performed within 7 days prior to enrollment) OR

    • a GFR ≥ 50 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard) (performed within 7 days prior to enrollment)

      • Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable if using GFR for determine eligibility
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age (performed within 7 days prior to enrollment)

  • Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) ≤ 135 U/L* (performed within 7 days prior to enrollment)

    • Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
  • Central nervous system function defined as:

    • Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled.
    • Patients must not be in status epilepticus, a coma or assisted ventilation at the time of study enrollment
  • Adequate cardiac function

    • Shortening fraction of ≥ 27% by echocardiogram, or

    • Ejection fraction of ≥ 50% by echocardiogram, cardiac MRI, or radionuclide angiogram, AND

    • For Patients ≥ 18 years:

      • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better
  • Test result showing no evidence of complete or partial absence of dihydropyrimidine dehydrogenase (DPYD) activity. This genetic test can be obtained at any time prior to enrollment at a College of American Pathology (CAP)/Clinical Laboratory Improvement Act (CLIA) certified laboratory. Patients with DPYD variants that result in complete or partial DPD deficiency are not permitted to enroll on this study

Exclusion Criteria:

  • Patients with metastatic disease by either MRI evaluation or lumbar CSF cytology are not eligible. Patients who are unable to undergo a lumbar puncture for assessment of CSF cytology are ineligible
  • Hypersensitivity to fluorouracil, tretinoin, other retinoids, or any component of the formulation
  • Personal history of Torsades de pointes, atrial fibrillation, supraventricular tachycardia (SVT), or heart failure; personal history of prolonged QT Syndrome; other uncontrolled arrhythmia in the past 6 months prior to study enrollment
  • Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
  • Lactating females who plan to breastfeed their infants
  • Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation. Patients who could become pregnant should use effective contraception during treatment and 1 month following the last dose of tretinoin or for 3 months following last dose of fluorouracil, whichever is longer. Patients with partners who could become pregnant should also use effective contraception during treatment and for 1 week after the last dose of tretinoin or 3 months after the last dose of fluorouracil, whichever is longer

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment (radiation, fluorouracil, tretinoin)

CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy over 6 or 7 weeks. Starting on day 1, 2 or 3 of radiation, patients receive fluorouracil IV over 3-15 minutes on days 1 and 15, days 1, 8 and 15, or days 1, 8, 15 and 22 depending upon assigned dose level. Treatment is given in the absence of disease progression or unacceptable toxicity.

MAINTENANCE CHEMOTHERAPY: Four weeks after completion of chemoradiotherapy, patients receive fluorouracil IV on days 1, 8, 15 and 22 of each cycle and tretinoin PO TID on days 1-3, 8-10, 15-17 and 22-24 of each cycle. Cycles repeat every 42 days for 6 cycles in the absence of disease progression or unacceptable toxicity.

Patients undergo echocardiography or MUGA, MRI, lumbar puncture, and optional blood sample collection throughout the study.

Given IV

其他名称:
  • 5-氟嘧啶
  • 氟嘧啶
  • 5氟尿嘧啶
  • 5 氟尿嘧啶
  • 5傅
  • 5-Fluoro-2,4(1H, 3H)-pyrimidinedione
  • 5-氟尿嘧啶
  • 5福
  • 5FU
  • 精确站点
  • 卡拉克
  • 氟尿嘧啶
  • 氟黄素
  • 氟里尔
  • 氟芽素
  • 氟核糖
  • 罗 2-9757
  • Ro-2-9757

Undergo MRI

其他名称:
  • 核磁共振
  • 磁共振
  • 磁共振成像扫描
  • 医学影像、磁共振/核磁共振
  • 先生
  • 磁共振成像
  • 核磁共振成像扫描
  • 核磁共振成像
  • 磁共振成像 (MRI)
  • 磁共振成像(程序)
  • 结构核磁共振

Undergo lumbar puncture

其他名称:
  • 唱片
  • 脊柱穿刺

Undergo MUGA scan

其他名称:
  • 血池扫描
  • 平衡放射性核素血管造影
  • 门控血池成像
  • 穆加
  • 放射性核素脑室造影
  • 导航导航仪
  • 司马扫描
  • 同步多门采集扫描
  • 穆加扫描
  • 多门控采集扫描
  • 放射性核素脑室造影扫描
  • 门控心池扫描
  • RNV扫描

Undergo echocardiography

其他名称:
  • 超声心动图
  • 欧共体

Undergo blood and CSF sample collection

其他名称:
  • 生物样本采集
  • 收集的生物样本
  • 标本采集
  • 样本收集

Undergo standard of care radiation therapy

其他名称:
  • 癌症放疗
  • 能源类型
  • 照射
  • 辐照
  • 辐射
  • 放射治疗,NOS
  • 放疗
  • 转播
  • 治疗、放射
  • 能量类型

Given PO

其他名称:
  • Vesanoid
  • 亚特拉
  • 雷诺瓦
  • 维甲酸
  • 气溶胶
  • 阿维塔
  • Stieva-A
  • 2,4,6,8-壬四烯酸, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-
  • 阿贝雷尔
  • 活动
  • 全反式维甲酸
  • 全反式维生素A酸
  • β-视黄酸
  • 德瓦斯
  • 美罗素
  • 埃皮阿贝雷尔
  • Eudyna
  • 维甲酸微量
  • 视黄酸
  • 视黄醇-A
  • 罗5488
  • Stieva-A Forte 系列
  • 反式维甲酸
  • 反式维生素A酸
  • 反式视黄酸
  • 维生素A酸
  • 维生素A酸,全反式
  • 维生素A

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Occurrence of dose limiting toxicity chemoradiotherapy (DLT) (phase 1)
大体时间:From the start of chemoradiotherapy until 4 weeks after completing chemoradiotherapy

Will report the sample proportion of analysis patients experiencing DLTs with binominal exact 95% confidence intervals by dose level. Other toxicity data will also be described as appropriate for supportive analyses.

From the start of chemoradiotherapy until 4 weeks after completing chemoradiotherapy
Occurrence of DLT for maintenance therapy (phase 1)
大体时间:From the start of the first maintenance therapy cycle until the end of the first maintenance therapy cycle (Cycle = 42 days)

Will report the sample proportion of analysis patients experiencing DLTs with binominal exact 95% confidence intervals by dose level. Other toxicity data will also be described as appropriate for supportive analyses. A planned supportive analysis will descriptively assess any interaction between increasing chemoradiotherapy dose and maintenance therapy tolerability.

From the start of the first maintenance therapy cycle until the end of the first maintenance therapy cycle (Cycle = 42 days)
Event free survival (EFS)
大体时间:From enrollment to the first of any of the following events: disease progression, disease recurrence, second malignant neoplasm, or death from any cause, up to 5 years

Will test whether the EFS in the prospective patients is superior to the historical control using a stratified log-rank test adjusting for resection status (subtotal resection [STR] or gross total resection/near total resection GTR/NTR]) with a one-sided type-1 error rate of 0.10. The primary analysis will also report the Kaplan-Meier estimates of the prospective and historical control patients. Planned supportive analyses will assess whether EFS differs by resection status within the prospective patients, and conduct separate resection status-specific comparisons between the prospective and corresponding historical control patients. These analyses will use unadjusted log-rank tests.

From enrollment to the first of any of the following events: disease progression, disease recurrence, second malignant neoplasm, or death from any cause, up to 5 years

次要结果测量

结果测量
措施说明
大体时间
Overall response
大体时间:After completing chemoradiotherapy (up to 49 days) and after completing maintenance therapy (Up to 6 cycles (Cycle= 42 days))

STR patients will be analyzed separately from GTR/NTR patients, as GTR/NTR patients are only evaluable for experiencing progressive disease. Analyses will also be reported separately by dose level. We will report the response rates using the respective sample proportions and exact binomial two-sided 95% confidence intervals.

After completing chemoradiotherapy (up to 49 days) and after completing maintenance therapy (Up to 6 cycles (Cycle= 42 days))
Overall survival
大体时间:From enrollment to death from any cause, up to 5 years

Will be summarized by the Kaplan Meyer method with similar considerations for the analysis population and intercurrent events as for EFS.

From enrollment to death from any cause, up to 5 years

其他结果措施

结果测量
措施说明
大体时间
Correlate presence of tumor cell free deoxyribonucleic acid (DNA) with methylation profiling and clinical outcome
大体时间:Up to 5 years

Will explore the associations between tumor cell free DNA and EFS using Cox models. Initial analyses will use univariable models, and suitable multivariable models will be considered, subject to data constraints (e.g., number of events).Cox models incorporating these covariates as baseline covariates will be used for covariates available at the time of enrollment, and landmark analyses or time-varying covariates will be used for analyses with post-enrollment covariates.

Up to 5 years
Correlate histopathologic grade with clinical outcome
大体时间:Up to 5 years

Will explore the associations between histopathologic grade and EFS using Cox models. Initial analyses will use univariable models, and suitable multivariable models will be considered, subject to data constraints (e.g., number of events).Cox models incorporating these covariates as baseline covariates will be used for covariates available at the time of enrollment, and landmark analyses or time-varying covariates will be used for analyses with post-enrollment covariates.

Up to 5 years
Correlate gene expression profiles with clinical outcome
大体时间:Up to 5 years

Will explore the associations between gene expression profiles and EFS using Cox models. Initial analyses will use univariable models, and suitable multivariable models will be considered, subject to data constraints (e.g., number of events).Cox models incorporating these covariates as baseline covariates will be used for covariates available at the time of enrollment, and landmark analyses or time-varying covariates will be used for analyses with post-enrollment covariates.

Up to 5 years
Correlate epigenetic profiles with clinical outcome
大体时间:Up to 5 years

Will explore the associations between epigenetic profiles and EFS using Cox models. Initial analyses will use univariable models, and suitable multivariable models will be considered, subject to data constraints (e.g., number of events).Cox models incorporating these covariates as baseline covariates will be used for covariates available at the time of enrollment, and landmark analyses or time-varying covariates will be used for analyses with post-enrollment covariates.

Up to 5 years
Correlate chromosome copy number status with clinical outcome
大体时间:Up to 5 years

Will explore the associations between chromosome copy number status and EFS using Cox models. Initial analyses will use univariable models, and suitable multivariable models will be considered, subject to data constraints (e.g., number of events).Cox models incorporating these covariates as baseline covariates will be used for covariates available at the time of enrollment, and landmark analyses or time-varying covariates will be used for analyses with post-enrollment covariates.

Up to 5 years
Bank tumor, blood and cerebrospinal fluid specimens for future studies and assessment of immune and molecular signatures
大体时间:Up to 5 years

The number of patients consenting to collect tumor, blood and cerebrospinal fluid specimens, along with the number of submitted specimens, will be recorded as a part of routine study monitoring.

Up to 5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Adam J Esbenshade、Children's Oncology Group

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月11日

初级完成 (估计的)

2037年6月30日

研究完成 (估计的)

2037年6月30日

研究注册日期

首次提交

2026年9月18日

首先提交符合 QC 标准的

2026年9月23日

首次发布 (实际的)

2026年9月30日

研究记录更新

最后更新发布 (实际的)

2026年9月30日

上次提交的符合 QC 标准的更新

2026年9月23日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅